The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template formularies, Novo said Thursday. CVS Caremark, which forms the eponymous pharmacy chain’s drug benefits unit, is the largest pharmacy benefit manager in the U.S., as Novo pointed out.

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will undo all that progress.

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.